BG Medicine, Inc. Welcomes Galectin-3 Clinical Research Data From the PROTECT Study Conducted at Massachusetts General Hospital

BG Medicine, Inc. Welcomes Galectin-3 Clinical Research Data From the PROTECT
Study Conducted at Massachusetts General Hospital Demonstrating Predictive
Value of Adverse Outcomes in Heart Failure Patients

WALTHAM, Mass., Sept. 23, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc.
(Nasdaq:BGMD) announced today the publication of the results of a clinical
research study conducted at the Massachusetts General Hospital (MGH) that
provide further evidence that elevated levels of galectin-3 are predictive of
adverse outcomes in chronic heart failure patients and suggest that the
prognostic value of this non-invasive biomarker may be enhanced when serial
measurements are made over time.

In this clinical research study, which was recently published online in the
European Journal of Heart Failure, first author Dr. Shweta Motiwala and
colleagues of the Division of Cardiology at the Massachusetts General Hospital
demonstrate that stable heart failure patients whose galectin-3 blood levels
were greater than 20 ng/ml, when measured at three-month intervals,
experienced 50% more cardiovascular events, including unplanned
hospitalizations for heart failure, than patients whose galectin-3 levels were
consistently lower than 20 ng/ml.^1 Further, these research data, which were
collected from over 900 outpatient visits, also found that increases in
galectin-3 levels above a threshold value of 20 ng/ml between outpatient
visits, and increases in galectin-3 levels in excess of 15% at any three-month
interval, were also predictive of significantly increased risk of adverse
outcomes, including unplanned hospitalizations.

"We believe that the results of this research study further support a large
body of evidence regarding the utility of galectin-3 as a predictor of adverse
outcomes inchronic heart failure," said Dr. Paul R. Sohmer, President and CEO
of BG-Medicine, Inc. "From this study, it appears that serial outpatient
testing for galectin-3 may provide additional information that may facilitate
decisions regarding the clinical management of stable heart failure patients."

For this clinical research study, galectin-3 levels were measured in plasma
samples that had been collected as part of the PROTECT study.^2 The study
enrolled 151 stable heart failure (HF) patients, with an average age of 63
years, who were followed for a median of 10 months. The HF patients who
participated in the study had galectin-3 blood levels drawn at four time
points during scheduled outpatient physician visits. Galectin-3 levels
independently predicted cardiovascular events even after adjustment for
clinically relevant variables such as treatment arm allocation, NT-proBNP
level, and kidney function. No effect on galectin-3 levels was observed in
association with heart failure medications that provided symptom-related or
mortality-related benefits.

"Unplanned hospitalizations and unforeseen cardiovascular events are
devastating to heart failure patients and their families, represent a
significant challenge to health care providers and continue to be a leading
cost burden on healthcare systems," stated Dr. Sohmer. "The results of this
study from the Massachusetts General Hospital provide further evidence that
galectin-3 testing may help to identify and facilitate triage of those heart
failure patients who are at elevated risk of near-term adverse events and of
deteriorating cardiac function."

The BGM Galectin-3® test is cleared by the FDA as an aid in assessing the
prognosis of patients diagnosed with chronic heart failure when used in
conjunction with clinical evaluation.

About Galectin-3 and Heart Failure

Galectin-3 has been implicated in a variety of biological processes important
in the development and progression of heart failure. Higher levels of
galectin-3 are associated with a more aggressive form of heart failure, which
may make identification of high-risk patients using galectin-3 testing an
important part of patient care. Galectin-3 testing may be useful in helping
physicians determine which patients are at higher risk of death or
hospitalization, including 30-day readmission. The BGM Galectin-3® test is to
be used as an aid in assessing the prognosis of patients with chronic heart
failure, in conjunction with clinical evaluation. For more information visit
www.galectin-3.com

About BG Medicine, Inc.

BG Medicine, Inc. (Nasdaq:BGMD) is a commercial stage company that is focused
on the development and delivery of diagnostic solutions to aid in the clinical
management of heart failure and related disorders. For additional information
about BG Medicine, heart failure and galectin-3 testing, please visit
www.BG-Medicine.com. The BG Medicine Inc. logo is available for download here

Forward Looking Statements

Certain statements made in this news release contain forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities and Exchange Act of 1934, as
amended, that are intended to be covered by the "safe harbor" created by those
sections. Forward-looking statements, which are based on certain assumptions
and describe our future plans, strategies and expectations, can generally be
identified by the use of forward-looking terms such as "believe," "expect,"
"may," "will," "should," "could," "seek," "intend," "plan," "estimate,"
"anticipate" or other comparable terms. Forward-looking statements in this
news release address our belief that the results of the MGH research study
further support a large body of evidence regarding the utility of galectin-3
as a predictor of adverse outcomes in stable heart failure; our understanding
that serial outpatient testing for galectin-3 may provide additional
information that may facilitate decisions regarding the clinical management of
stable heart failure patients; and our understanding that the results of the
MGH study provide further evidence that galectin-3 testing may help to
identify and facilitate triage of those heart failure patients who are at
elevated risk of near-term adverse events and of deteriorating cardiac
function. Forward-looking statements are based on management's current
expectations and involve inherent risks and uncertainties which could cause
actual results to differ materially from those in the forward-looking
statements, as a result of various factors including those risks and
uncertainties described in the Risk Factors and in Management's Discussion and
Analysis of Financial Condition and Results of Operations sections of our
recent filings with the Securities and Exchange Commission, including our most
recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We urge
you to consider those risks and uncertainties in evaluating our
forward-looking statements. We caution readers not to place undue reliance
upon any such forward-looking statements, which speak only as of the date
made. Except as otherwise required by the federal securities laws, we disclaim
any obligation or undertaking to publicly release any updates or revisions to
any forward-looking statement contained herein (or elsewhere) to reflect any
change in our expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based.

Publication References

1. Motiwala SR, Szymonifka J, et al. Serial measurement of galectin-3 in
patients with chronic heart failure: results from the ProBNP Outpatient
Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail. 2013
May 10.

2. Gaggin HK, Mohammed AA, et al. Heart failure outcomes and benefits of
NT-proBNP-guided management in the elderly: results from the prospective,
randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT)
study. J Card Fail. 2012 Aug;18(8):626-34.

CONTACT: BG-Medicine Investor Inquiries:
         Chuck Abdalian, EVP & Chief Financial Officer, (781) 434-0210
         BG Medicine, Inc.

BG Medicine Inc. logo